Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lisa Hurd

Clinical Nurse Specialist, Adult Health Jonesboro, AR Nurse Practitioner

NPI 1740565324 CMS profile 10580299

300 Carson St, Jonesboro, AR 72401

Open in the dashboard

General payments

$12,083

635 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Hurd of Jonesboro, AR is reported in the CMS Open Payments database as having received $12,083 across 635 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,178 160
2024 General $3,291 171
2023 General $2,339 115
2022 General $1,425 74
2021 General $1,850 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Hurd
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Lisa Hurd were reported at $3,178. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Lisa Hurd Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,850 $133 $48–$445 $132
2022 $1,425 $163 $57–$526 $149
2023 $2,339 $173 $64–$597 $160
2024 $3,291 $171 $54–$575 $164
2025 $3,178 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Daiichi Sankyo Inc. $998 32 payments
  2. Novartis Pharmaceuticals Corporation $870 55 payments
  3. Janssen Biotech, Inc. $857 50 payments
  4. Merck Sharp & Dohme Corporation $752 44 payments
  5. AstraZeneca Pharmaceuticals LP $532 23 payments
  6. Incyte Corporation $520 23 payments
  7. Pfizer Inc. $515 34 payments
  8. GlaxoSmithKline, LLC. $481 28 payments
  9. Exelixis Inc. $430 22 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $409 19 payments
  11. Other $5,718 305 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,408 625 payments
  2. Education $674 10 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $724 42 payments
  2. INJECTAFER $421 14 payments
  3. IMBRUVICA $388 18 payments
  4. Lenvima $336 18 payments
  5. IMFINZI $264 8 payments
  6. MONJUVI $260 15 payments
  7. EPKINLY $257 11 payments
  8. NINLARO $255 12 payments
  9. ENHERTU $246 12 payments
  10. DARZALEX $244 14 payments
  11. Other $10,202 597 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

378

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$424,605

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

18.5%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Imbruvica Ibrutinib Brand 26 $420,015
Letrozole Generic 52 $682
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 25 $648
Dexamethasone Generic 24 $471
Ondansetron Odt Ondansetron Brand 19 $451
Potassium Chloride Generic 35 $433
Acyclovir Generic 44 $411
Hydroxyurea Generic 19 $372
Prochlorperazine Maleate Generic 25 $368
Gabapentin Generic 33 $270

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$16,098

Medicare's payments for the services billed

Medicare patients

134

Average age 73

Services billed

364

79 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 46%
Cancer 43%
Ischemic heart disease 41%
Depression 37%
COPD 35%
Chronic kidney disease 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 67 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IMFINZI
  • AstraZeneca Pharmaceuticals LP $164
$164 — —
ENHERTU
  • Daiichi Sankyo Inc. $93
  • AstraZeneca Pharmaceuticals LP $64
$157 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $146
$146 — —
Lenvima
  • Eisai Inc. $137
$137 — —
INJECTAFER
  • Daiichi Sankyo Inc. $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 67 with Patron

Records

635 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record